Clough Capital Partners L P Bluebird Bio, Inc. Transaction History

Clough Capital Partners L P

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $1.29 Million - $2.04 Million	-21,850 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $1.16 Million - $1.54 Million	-13,100 Reduced 37.48%	21,850 $3.19 Million
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $2.81 Million - $3.6 Million	28,230 Added 420.09%	34,950 $5.49 Million
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $275,080 - $392,444	2,600 Added 63.11%	6,720 $1.15 Million
Q4 2017 Feb 14, 2018	SELL	$81.25 - $130.7 $87,750 - $141,156	-1,080 Reduced 20.77%	4,120 $734,000
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $300,248 - $475,384	5,200	5,200 $714,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $23.1M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Clough Capital Partners L P, based on Form 13F filings with the SEC.

Stay updated on Clough Capital Partners L P with notifications on news.